Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCMA-directed CAR-T cell
- Development stage
- Unknown
- Modality
- CAR-T Cells → Engineered T Cells → Adoptive Cell Transfer → Cell Therapies
- Administration
- Intravenous
01
Overview
BCMA-directed CAR-T cell therapy is a type of immunotherapy that involves genetically modifying a patient's own T cells to express a chimeric antigen receptor (CAR) that specifically targets B-cell maturation antigen (BCMA). BCMA is a protein found on the surface of multiple myeloma cells and other plasma cells. Upon infusion, these modified CAR-T cells recognize and bind to BCMA-expressing cells, leading to their destruction. This therapy has shown significant efficacy in treating relapsed or refractory multiple myeloma and is also being investigated for non-oncology plasma cell-related diseases like generalized myasthenia gravis.
02
Targets
BCMA (B-cell maturation antigen)
Beyond the preview
Go deeper on BCMA-directed CAR-T cell.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCMA-directed CAR-T cell.